10-Q
Quarterly Report
ADIAL PHARMACEUTICALS, INC.
ADIL
NASDAQ
CIK: 1513525
File #: 001-38323
Balance Sheet
25 line items · 2 periods
XBRL
| Item | Mar 31, 2025 | Dec 31, 2024 |
|---|---|---|
Current Assets: | ||
Cash and cash equivalents | 2,365,780 | 3,750,525 |
Prepaid expenses and other current assets | 263,395 | 308,239 |
Total Current Assets | 2,629,175 | 4,058,764 |
Equity Method Investments | — | 672,330 |
Intangible assets, net | 3,207 | 3,348 |
Equity method investment | 818,740 | 981,830 |
Equity Method Investments | 818,740 | 981,830 |
Total Assets | 3,451,122 | 5,043,942 |
Current Liabilities: | ||
Accounts payable | 532,430 | 250,130 |
Related Party | 33,335 | 48,272 |
Accrued expenses | 758,695 | 677,456 |
Total Current Liabilities | 1,324,460 | 975,858 |
Equity Method Investments | — | 1,232,344 |
Total Liabilities | 1,324,460 | 975,858 |
Stockholders’ Equity | ||
Common Stock, 50,000,000 shares authorized with a par value of $0.001 per share, 6,649,588 and 6,474,588 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | 6,650 | 6,473 |
Additional paid in capital | 86,344,136 | 86,056,934 |
Accumulated deficit | (84,224,124) | (81,995,323) |
Total Stockholders’ Equity | 2,126,662 | 4,068,084 |
Common Stock | 6,650 | 6,473 |
Additional Paid In Capital | 86,344,136 | 86,056,934 |
Accumulated Deficit | (84,224,124) | (81,995,323) |
Total Liabilities and Stockholders’ Equity | 3,451,122 | 5,043,942 |